Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
复制标题
DOI：
10.1186/1756-8722-2-23
复制
发表时间：
2009-06-02
影响因子：
28.5
通讯作者：
Tse W
中科院分区：
文献类型：
--
作者：
Gregory TK;Wald D;Chen Y;Vermaat JM;Xiong Y;Tse W
急性髓系白血病(AML)是一种异质性疾病，其原因是造血祖细胞分化受阻，并伴有不受控制的增殖。在大约60%的病例中，特定的复发性染色体异常可以通过现代细胞遗传学技术识别出来。这种细胞遗传学信息是将患者在最初诊断时分为三种预后类别的最重要的工具：良好、中等和不良风险。目前，风险好的急性髓细胞白血病患者通常接受同期化疗，而风险低的急性髓细胞白血病患者如果有合适的干细胞捐赠者，则接受异基因干细胞移植。AML患者中最大的亚群(约40%)没有可识别的细胞遗传学异常，被归类为中等风险。这些患者的最佳治疗策略在很大程度上仍不清楚。最近，越来越明显的是，在细胞遗传学正常的急性髓细胞白血病(NC-AML)患者中识别风险较低的患者亚群是可能的。由于NPM1、Flt3、MLL和CEBPα突变以及BAALC、MN1、ERG和AF1q表达水平的变化，NC-AML患者的分子风险分层可能是可能的。需要进一步的前瞻性研究来证实风险较低的NC-AML患者在接受更积极的治疗后是否改善了临床结果。
Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist. The largest subgroup of AML patients (~40%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk. The optimal therapeutic strategies for these patients are still largely unclear. Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML (NC-AML). Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPα as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q. Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.
登录
查看更多内容
影响因子：
158.5
作者：
Falini, B;Mecucci, C;Martelli, MF
通讯作者：
Martelli, MF
影响因子：
2.6
作者：
Bacher, Ulrike;Badbaran, Anita;Kroeger, Nicolaus
通讯作者：
Kroeger, Nicolaus
影响因子：
20.3
作者：
Gale, RE;Hills, R;Linch, DC
通讯作者：
Linch, DC
影响因子：
3.7
作者：
Mrózek, K;Heinonen, K;Bloomfield, CD
通讯作者：
Bloomfield, CD
影响因子：
3.7
作者：
Debernardi, S;Lillington, DM;Young, BD
通讯作者：
Young, BD